Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: g.w. barnard who wrote (9318)	6/7/1998 10:21:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

gw, $2.00/share for 1999 IMO is indeed a conservative estimate considering lower production costs at the new plant and international sales. They say the street looks at earnings potential at least 6 to 9 months out (usually more). I wish a few larger brokerages would initiate coverage on Vivus. The current anal_ysts seem to be unable to look at solid facts about the ED market and the potential for growth with Vivus. I have a hunch that as soon as script numbers start to go up we will see an upgrade from James Kelly at CS First Boston (I noticed some heavy accumulating by them the past 2 trading days). Of all the brokerages covering CS First Boston probably pulls the most weight. If an obscure bucket shop Anal_yst could help tank the price last week along with the slanted journalism, I would hate to be short when a well respected brokerage puts out a buy recommendation.